Significance of an activator of neuronal cyclin dependent kinase 5 in developmental change of tau phosphorylation that is also observed in alzheimer's disease brain

1994 ◽  
Vol 1 ◽  
pp. 383
Author(s):  
K. Ishiguro ◽  
J. Ohnuma ◽  
M. Takamatsu ◽  
S. Yonekura ◽  
K. Imahori ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Developmental Change ◽  
Tau Phosphorylation ◽  
Cyclin Dependent Kinase ◽  
Cyclin Dependent Kinase 5

scholarly journals Oral Amylin Treatment Reduces the Pathological Cascade of Alzheimer’s Disease in a Mouse Model

2021 ◽  
Vol 36 ◽  
pp. 153331752110128
Author(s):  
Hana Na ◽  
Hua Tian ◽  
Zhengrong Zhang ◽  
Qiang Li ◽  
Jack B. Yang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Calcium Binding ◽  
Oral Delivery ◽  
Amyloid Β ◽  
Enteric Neurons ◽  
Cyclin Dependent Kinase ◽  
Receptor Activity Modifying Proteins ◽  
The Brain ◽  
Cyclin Dependent Kinase 5

Intraperitoneal injection of amylin or its analog reduces Alzheimer’s disease (AD) pathology in the brains. However, self-injecting amylin analogs is difficult for patients due to cognitive deficits. This work aims to study the effects of amylin on the brain could be achieved by oral delivery as some study reported that amylin receptor may be present in the gastrointestinal tract. A 6-week course of oral amylin treatment reduced components of AD pathology, including the levels of amyloid-β, phosphorylated tau, and ionized calcium binding adaptor molecule 1. The treatment reduced active forms of cyclin-dependent kinase 5. Oral amylin treatment led to improvements in social deficit in AD mouse. Using immunofluorescence, we observed the amylin receptor complexed with the calcitonin receptor and receptor activity-modifying proteins in the enteric neurons. The study suggests the potential of the oral delivery of amylin analogs for the treatment of AD and other neurodegenerative diseases through enteric neurons.

Cyclin-Dependent Kinase 5 Activator p25 Is Generated During Memory Formation and Is Reduced at an Early Stage in Alzheimer's Disease

2011 ◽  
Vol 70 (2) ◽  
pp. 159-168 ◽  
Author(s):  
Olivia Engmann ◽  
Tibor Hortobágyi ◽  
Andrew J. Thompson ◽  
Jennifer Guadagno ◽  
Claire Troakes ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Stage ◽  
Memory Formation ◽  
Cyclin Dependent Kinase ◽  
Cyclin Dependent Kinase 5

A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer’s disease

2007 ◽  
Vol 15 (19) ◽  
pp. 6397-6406 ◽  
Author(s):  
Mahendra Ramesh Shiradkar ◽  
Mallikarjuna Bandrehally Padhalingappa ◽  
Sastry Bhetalabhotala ◽  
Kalyan Chakravarthy Akula ◽  
Dattu Anna Tupe ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Potential Treatment ◽  
Cyclin Dependent Kinase ◽  
Novel Approach ◽  
Cyclin Dependent Kinase 5

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer’s disease

2009 ◽  
Vol 19 (19) ◽  
pp. 5703-5707 ◽  
Author(s):  
Christopher J. Helal ◽  
Zhijun Kang ◽  
John C. Lucas ◽  
Thomas Gant ◽  
Michael K. Ahlijanian ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cyclin Dependent Kinase ◽  
Cyclin Dependent Kinase 5
Sign in / Sign up

Export Citation Format

Share Document